Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
Rhenium-186 (tin) hydroxyethylidene diphosphonate (HEDP) is a new radiopharmaceutical that simultaneously localizes in multiple skeletal metastases in patients with advanced cancer. A single intravenous administration of 30-35 mCi (1110-1295 MBq) is associated with a prompt, significant relief of osseous pain in about 80% of such patients. The efficacy of this new compound was evaluated further by utilizing a double-blind crossover comparison with 99mTc-methylene diphosphonate (MDP) as a radioactive placebo. The new rhenium compound resulted in a significantly (p less than 0.05) greater decrease in pain than did treatment with the radioactive placebo. Rhenium-186(Sn)HEDP appears to be a useful new compound for the palliation of painful skeletal metastases.
Maxon
H R
HR
Department of Radiology, Eugene L. Saenger Radioisotope Laboratory, University of Cincinnati Medical Center, OH 45267-0577.
Schroder
L E
LE
Hertzberg
V S
VS
Thomas
S R
SR
Englaro
E E
EE
Samaratunga
R
R
Smith
H
H
Moulton
J S
JS
Williams
C C
CC
Ehrhardt
G J
GJ
D000368:Aged; D001859:Bone Neoplasms / Q000503:physiopathology / Q000556:secondary*; D004311:Double-Blind Method; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010148:Intractable Pain / Q000209:etiology / Q000532:radiotherapy*; D010166:Palliative Care / Q000379:methods*; D011471:Prostatic Neoplasms / Q000473:pathology; D011868:Radioisotopes / Q000627:therapeutic use*; D012211:Rhenium / Q000627:therapeutic use*; D013669:Technetium Tc 99m Medronate / Q000627:therapeutic use
D009942:Organometallic Compounds; D011868:Radioisotopes; C064573:rhenium-186(tin)etidronate; D012211:Rhenium; D012968:Etidronic Acid; D013669:Technetium Tc 99m Medronate